关联交易

Search documents
天虹股份: 第六届董事会第三十五次会议决议公告
Zheng Quan Zhi Xing· 2025-09-01 12:19
Group 1 - The company held its 35th meeting of the 6th Board of Directors on September 1, 2025, via communication, with all 9 directors present, complying with relevant regulations [1] - The Board approved the election of non-independent director candidates for the 7th Board, including Xiao Zhanglin, Huang Junkang, Huang Guojun, Hu Min, and Guo Gaohang, with a unanimous vote of 9 in favor [1][2] - The Board also approved the election of independent director candidates, including Zeng Quan, Chen Liping, and Pan Shoupei, with a unanimous vote of 9 in favor [2] Group 2 - The Board approved the revision of the company's fundraising management system, which will be submitted for shareholder meeting review [2][3] - The Board agreed to change the lease contract with Shenzhen Zhonghang Guanlan Real Estate Development Co., Ltd., shortening the lease term to February 23, 2029, with a total transaction amount for the remaining contract period [3] - The Board proposed to hold the company's second extraordinary general meeting of shareholders in 2025, with a unanimous vote of 9 in favor [4] Group 3 - The resumes of the nominated candidates for the 7th Board of Directors were provided, detailing their qualifications and current positions [5][6][7][8][9][10][11][12][13][14][15]
*ST亚振: 关于第五届董事会第十二次会议决议公告
Zheng Quan Zhi Xing· 2025-09-01 11:08
Group 1 - The board of directors of Yazhen Home Co., Ltd. held its 12th meeting of the 5th session, with all 5 directors present, complying with relevant laws and regulations [1] - The board unanimously approved the appointment of Zhongshun Yatai Accounting Firm as the auditor for the fiscal year 2025, citing their experience and capability to meet the company's audit requirements [1] - The proposal regarding related party transactions of the subsidiary Guangxi Zr Technology Co., Ltd. was also approved, with independent directors confirming that the transactions are fair and do not harm the interests of the company or its shareholders [2][3] Group 2 - The appointment of the accounting firm and the related party transaction proposals will be submitted to the shareholders' meeting for further approval [2][3] - The independent directors emphasized that the related party transactions are based on market conditions and do not compromise the company's independence [2]
华域汽车溢价46%和936%收购上汽两亏损资产 回款连续6年恶化、近半收入依赖上汽
Xin Lang Zheng Quan· 2025-09-01 10:18
Core Viewpoint - Huayu Automotive plans to acquire 49% of Shanghai SAIC Qingtao Energy Technology Co., Ltd. for 210 million yuan and 5.3% of Lianchuang Automotive Electronics Co., Ltd. for 150 million yuan, marking its entry into solid-state battery and integrated intelligent chassis businesses [1][2]. Group 1: Acquisition Details - The acquisition of SAIC Qingtao involves a premium of 46% over its assessed value of 420 million yuan compared to its book value of 288 million yuan [4]. - The acquisition of Lianchuang Electronics shows an even higher premium of 936%, with an assessed value of 2.923 billion yuan against a book value of 282 million yuan [6]. Group 2: Financial Performance of Acquired Companies - SAIC Qingtao is projected to have revenues of nearly zero in 2024 and 2025, with net losses of 63.35 million yuan and 40.68 million yuan respectively [3]. - Lianchuang Electronics is also in a loss position, with revenues of 1.516 billion yuan and 838 million yuan for the same periods, and net losses of 152 million yuan and 53 million yuan [5]. Group 3: Huayu Automotive's Financial Health - Huayu Automotive has seen a decline in accounts receivable turnover days from 56 days in 2018 to 97 days in the first half of 2024, indicating worsening cash flow [8][9]. - The proportion of revenue from SAIC has been significant, accounting for approximately 50% and 38% of total revenue in 2022 and 2024 respectively [11].
阳光诺和: 2025年第三次临时股东会会议资料
Zheng Quan Zhi Xing· 2025-09-01 09:11
Core Viewpoint - The company is convening its third extraordinary general meeting of shareholders in 2025 to discuss and vote on key proposals, including a cooperation framework agreement with Dongfang Yanmei (Chengdu) Biotechnology Co., Ltd. and adjustments to daily related party transactions [1][12]. Meeting Procedures - Shareholders and their representatives must arrive 30 minutes before the meeting to sign in and present identification [2]. - The meeting will follow a structured agenda, including the announcement of the number of shareholders present and their voting rights [7]. - Shareholders have the right to speak, inquire, and vote during the meeting, with specific rules governing the conduct of discussions and questions [3][4]. Voting and Decision-Making - Voting will be conducted through both on-site and online methods, with results announced at the end of the meeting [5][6]. - Shareholders must express their opinions on the proposals as either in favor, against, or abstaining, and must sign their ballots [4][5]. Proposed Agreements - The company plans to sign a cooperation framework agreement with Dongfang Yanmei, which includes a procurement cap of CNY 10 million for 2025, CNY 20 million for 2026, and CNY 20 million for 2027 [12][13]. - The agreement aims to leverage both parties' resources for mutual benefit in the pharmaceutical research and development sector [12][17]. Related Party Transactions - The company is adjusting its expected daily related party transaction limits based on operational needs and market pricing [11][12]. - The adjustments are necessary for maintaining normal business operations and are expected to enhance market competitiveness and operational efficiency [12][17]. Financial and Operational Context - The company has established a stable relationship with its related parties, ensuring that these transactions do not adversely affect its independence or financial health [12][17]. - The cooperation with Dongfang Yanmei is positioned as a strategic move to enhance the company's capabilities in clinical trials and related services [12][17].
千亿龙头 重组预案出炉!明日复牌
Zhong Guo Zheng Quan Bao· 2025-08-31 22:57
Core Viewpoint - The company plans to acquire a 97.4988% stake in Shanghai Huali Microelectronics Co., Ltd. through a combination of share issuance and cash payment, while also raising supporting funds from specific investors [1][3]. Group 1: Transaction Details - The company will issue shares at a price of 43.34 yuan per share, which is not less than 80% of the average trading price over the previous 120 trading days [3]. - The total amount of supporting funds raised will not exceed 100% of the transaction price for the asset acquisition [3]. - The funds will be used for working capital, debt repayment, cash consideration, and project construction, with a maximum of 25% of the asset transaction price allocated for working capital and debt repayment [3]. Group 2: Financial Performance - In the first half of 2025, the company achieved a revenue of 8.018 billion yuan, a year-on-year increase of 19.09%, but the net profit attributable to the parent company decreased by 71.95% to 74.3154 million yuan [5]. - The acquisition of Huali Micro will enhance the company's total assets, net assets, revenue, and net profit, thereby improving its operational capabilities [5]. Group 3: Strategic Implications - The transaction is expected to create synergies in technology and operational efficiency, enhancing the company's competitive edge in logic and specialty processes [6]. - The integration of resources and management will lead to cost reduction and efficiency improvement, increasing market share and profitability [6].
华虹公司: 董事会关于本次交易是否构成重大资产重组、重组上市、关联交易的说明
Zheng Quan Zhi Xing· 2025-08-31 10:13
Group 1 - The company plans to acquire 97.4988% equity of Huali Microelectronics from four shareholders through a combination of issuing shares and cash payment [1][2] - The transaction is not expected to meet the criteria for a major asset restructuring as per the regulations, based on preliminary financial data of the target company [1] - The company will provide a detailed analysis and disclosure regarding the classification of the transaction in the restructuring report [1] Group 2 - The transaction is not expected to result in a change of control, as the controlling shareholder remains the same, thus it does not constitute a restructuring listing [1] - The transaction is classified as a related party transaction due to the involvement of the indirect controlling shareholder and a company where a board member serves as a director [2]
茂化实华: 关于公司与特定对象签署附条件生效的股份认购协议暨关联交易的公告
Zheng Quan Zhi Xing· 2025-08-31 08:12
证券代码:000637 证券简称:茂化实华 公告编号:2025-043 茂名石化实华股份有限公司 关于公司与特定对象签署附条件生效的股份认购协议 暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整, 本公司及董事会全体成员保证信息披露的内容真实、准确、完 没有虚假记载、误导性陈述或重大遗漏。 整,没有虚假记载、误导性陈述或重大遗漏。 (一)茂名石化实华股份有限公司(以下简称"茂化实 华""公司"或"上市公司")拟向特定对象发行 A 股股票, 发行数量不超过 155,962,606 股(含本数),即不超过发行 前公司总股本的 30%,全部由茂名港集团有限公司(以下简 称"茂名港")认购。本次向特定对象发行 A 股股票的定价 基准日为公司第十三届董事会第十次临时会议决议公告日, 本次发行的发行价格为 3.41 元/股。本次向特定对象发行股 票募集资金总额不超过 53,183.24 万元(含本数),扣除发 行费用后的募集资金净额拟全部用于补充流动资金。 (二)2025 年 8 月 29 日,公司与茂名港签署了《茂名 石化实华股份有限公司与茂名港集团有限公司关于茂名石化 实华股份有限公司向特定 ...
华扬联众数字技术股份有限公司2025年第五次临时股东会决议公告
Shang Hai Zheng Quan Bao· 2025-08-30 03:55
证券代码:603825 证券简称:ST华扬公告编号:2025-099 华扬联众数字技术股份有限公司 2025年第五次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: ● 本次会议是否有否决议案:无 一、会议召开和出席情况 (一)股东会召开的时间:2025年8月29日 (二)股东会召开的地点:湖南省长沙市岳麓区天顶街道环湖路1177号方茂苑(二期)13栋房产917室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况: ■ (一)非累积投票议案 1、议案名称:关于公司与关联方共同投资设立合资公司暨关联交易的议案 (四)表决方式是否符合《公司法》及《公司章程》的规定,大会主持情况等。 本次会议由公司董事会召集,董事长张利刚先生现场主持本次会议。本次股东会的召集、召开与表决程 序均符合《中华人民共和国公司法》及《华扬联众数字技术股份有限公司章程》的规定。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事7人,出席7人; 2、公司在任监事3人,出席3人; 3、公司董事会秘书 ...
上海农村商业银行股份有限公司2025年半年度报告摘要
Shang Hai Zheng Quan Bao· 2025-08-30 01:13
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:601825 证券简称:沪农商行 公告编号:2025-036 第一节 重要提示 1.1 本半年度报告摘要来自半年度报告全文,为全面了解本公司的经营成果、财务状况及未来发展规 划,投资者应当到上海证券交易所网站(http://www.sse.com.cn)网站仔细阅读半年度报告全文。 1.2 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、完整 性,不存在虚假记载、误导性陈述或重大遗漏,并承担法律责任。 1.4 本公司按中国会计准则编制的2025年半年度财务报告已经毕马威华振会计师事务所(特殊普通合 伙)根据中国审阅准则审阅,并出具了无保留结论的审阅报告。 1.5 经2025年6月13日召开的2024年度股东大会批准,本公司已向截至2025年6月26日收市后登记在册的 普通股股东派发了2024年度末期现金红利,对普通股每10股分配现金红利1.93元(含税),共计18.61亿 元(含税)。2024年度股东大会授权董事会制定了2025年中期利润分配方案:以实施权益分派股权登记 日登记的总股本为基数,对普通股每10股分配现金 ...
广州达安基因股份有限公司
Shang Hai Zheng Quan Bao· 2025-08-29 22:41
Group 1 - The company reported total assets of 11,191.56 million yuan and net assets of 2,228.54 million yuan as of June 30, 2025, with an operating income of 0.00 million yuan and a net loss of 45.18 million yuan [2] - The company has a stake of 33.24% in Guangzhou Changtong Medical Technology Co., Ltd., which constitutes an associated relationship [2] - Shanghai Dashan Biotechnology Co., Ltd. is a subsidiary in which the company holds a 21.788% stake, establishing an associated relationship [3] Group 2 - YunKang Health Industry Investment Co., Ltd. is another subsidiary where the company holds a 46.9566% stake, indicating an associated relationship [6] - Guangzhou Sai Jun Biotechnology Co., Ltd. is a joint venture with a 32.63% stake held by the company, also indicating an associated relationship [8] - Guangzhou Financial Holdings Group Co., Ltd. holds a total of 31.63% of the company's shares through its subsidiaries, establishing an associated relationship [10] Group 3 - The company expects to have daily related transactions with Guangzhou Tiancheng Medical Technology Co., Ltd. not exceeding 0.50 million yuan in 2025 [11] - Expected daily related transactions with Guangzhou Changtong Medical Technology Co., Ltd. and its subsidiaries are projected to be no more than 0.01 million yuan [12] - The company anticipates daily related transactions with Shanghai Dashan Biotechnology Co., Ltd. to be up to 5.00 million yuan [13] Group 4 - The company follows a pricing policy based on market fair prices for its related transactions, ensuring transparency and fairness [16] - All related transactions are formalized through written agreements detailing transaction terms, pricing principles, and payment methods [17] - The purpose of these transactions is to support the company's operations and development, leveraging the advantages of associated parties to enhance sales and reduce costs [18] Group 5 - The independent directors of the company have reviewed and approved the related transaction proposals, affirming their alignment with the company's strategic development and benefit to overall efficiency [19] - The board's decision-making process regarding these transactions adhered to legal and regulatory requirements, ensuring no harm to the interests of shareholders [19]